Case Report: Metastatic duodenal hepatoid adenocarcinoma: a rare pathology with exceptional response to dual immune checkpoint blockade
5 affiliations
- 1Department of Hematology Oncology, Lehigh Valley Health Network , , ,
- 2Department of Hematology Oncology, WellSpan Health , , ,
- 3Department of Radiology, Lehigh Valley Health Network , , ,
- 4Department of Pathology, Lehigh Valley Health Network , , ,
- 5Tufts University , , ,
Abstract
Hepatoid adenocarcinoma (HAC) is a rare, malignant, extrahepatic tumor with hepatocellular differentiation. HAC is often associated with elevated serum alpha-fetoprotein (AFP) concentrations, which makes it difficult to distinguish from primary hepatocellular carcinoma (HCC). It is a difficult diagnosis based on histopathology, as the immunohistochemistry (IHC) profile often overlaps with hepatocellular carcinoma. HAC can arise from multiple organs, including the stomach, esophagus, colon, pancreas, duodenum, and peritoneum, with the stomach being the most common site. The treatment of HAC is not well defined, as randomized trial data is not available. The overall prognosis of metastatic HAC with standard combination chemotherapy is extremely poor. Here, we present a case of metastatic duodenal HAC that achieved a sustained complete response to chemotherapy-free dual immune checkpoint blockade, which, to our knowledge, represents the first published report of a sustained complete response to chemotherapy-free dual immune checkpoint blockade in metastatic duodenal HAC and suggests a potential approach that warrants further clinical investigation. We acknowledge that a degree of diagnostic uncertainty remains, as HAC and HCC can exhibit essentially identical morphologic and immunophenotypic features, making the distinction largely clinical.
Related
- Longitudinally Extensive Hemorrhagic Myelitis in a Young Adult With Newly Diagnosed Duodenal Adenocarcinoma.
- Absence of Viable Tumor Cells in Macroscopically Pigmented Regional Lymph Nodes after Immune Checkpoint Inhibitor Therapy in Duodenal Metastasis of Cutaneous Melanoma: A Case Report.
- Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer
- Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer
- Refractory Hyperglycemia in Metastatic Adenocarcinoma: A Case of Suspected Paraneoplastic Hyperglucagonemia
BibTeX
@article{gupta2026case,
title = {{Case Report: Metastatic duodenal hepatoid adenocarcinoma: a rare pathology with exceptional response to dual immune checkpoint blockade}},
author = {Ranju Gupta and Darshan Lal and Rohit Walia and Shanth Goonewardene and Elizabeth Dellers and Kanchan Gupta},
journal = {Frontiers in oncology},
year = {2026},
month = sep,
doi = {10.3389/fonc.2026.1896620},
url = {https://europepmc.org/article/PMC/PMC13661362},
note = {CC BY},
}
RIS
TY - JOUR
TI - Case Report: Metastatic duodenal hepatoid adenocarcinoma: a rare pathology with exceptional response to dual immune checkpoint blockade
AU - Ranju Gupta
AU - Darshan Lal
AU - Rohit Walia
AU - Shanth Goonewardene
AU - Elizabeth Dellers
AU - Kanchan Gupta
PY - 2026
DA - 2026/09/30
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1896620
UR - https://europepmc.org/article/PMC/PMC13661362
AB - Hepatoid adenocarcinoma (HAC) is a rare, malignant, extrahepatic tumor with hepatocellular differentiation. HAC is often associated with elevated serum alpha-fetoprotein (AFP) concentrations, which makes it difficult to distinguish from primary hepatocellular carcinoma (HCC). It is a difficult diagnosis based on histopathology, as the immunohistochemistry (IHC) profile often overlaps with hepatocellular carcinoma. HAC can arise from multiple organs, including the stomach, esophagus, colon, pancreas, duodenum, and peritoneum, with the stomach being the most common site. The treatment of HAC is not well defined, as randomized trial data is not available. The overall prognosis of metastatic HAC with standard combination chemotherapy is extremely poor. Here, we present a case of metastatic duodenal HAC that achieved a sustained complete response to chemotherapy-free dual immune checkpoint blockade, which, to our knowledge, represents the first published report of a sustained complete response to chemotherapy-free dual immune checkpoint blockade in metastatic duodenal HAC and suggests a potential approach that warrants further clinical investigation. We acknowledge that a degree of diagnostic uncertainty remains, as HAC and HCC can exhibit essentially identical morphologic and immunophenotypic features, making the distinction largely clinical.
SN - 2234-943X
ER -